Therapy Directory

Cetuximab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Cetuximab as a study intervention. Browse Cetuximab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

559

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Chordoma, Unresectable Malignant Neoplasm
Interventions: Aldoxorubicin Hydrochloride, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, Avelumab, Cetuximab, Cyclophosphamide, SBRT; Biological · Drug · Radiation
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: El Segundo, California

Conditions: Metastatic Breast Cancer
Interventions: Irinotecan + Carboplatin, irinotecan + Carboplatin + erbitux; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2026
U.S. locations: 59
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 53 more

Conditions: Head and Neck Cancer
Interventions: ASP-1929 Photoimmunotherapy, Physician's Choice SOC; Combination Product · Drug
Lead sponsor: Rakuten Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia + 3 more

Conditions: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions: Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation; Radiation · Drug · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 5
States / cities: Gainesville, Florida • Chapel Hill, North Carolina • Hendersonville, North Carolina + 2 more

Conditions: Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck, Cancer of the Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck
Interventions: nab-Paclitaxel, Cisplatin, Cetuximab, Intensity-Modulated Radiation Therapy; Drug · Biological · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 3
States / cities: Westwood, Kansas • St Louis, Missouri • Sioux Falls, South Dakota

Conditions: Colorectal Cancer
Interventions: bevacizumab, cetuximab, FOLFIRI regimen, FOLFOX regimen, capecitabine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, mitomycin C, oxaliplatin, therapeutic conventional surgery; Biological · Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Baltimore, Maryland • Winston-Salem, North Carolina

Conditions: Colorectal Cancer Metastatic, mCRC
Interventions: Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT; Biological · Drug · Procedure
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: El Segundo, California

Conditions: BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, NRAS Gene Mutation Negative, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions: Cetuximab, Irinotecan, Panitumumab, Regorafenib; Biological · Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 15
States / cities: Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 12 more

Conditions: Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor, Recurrent Solid Tumor, Head and Neck Cancer
Interventions: NT219, NT219 and ERBITUX® - Dose Escalation, NT219 and ERBITUX® - Expansion; Drug
Lead sponsor: TyrNovo Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Encinitas, California • Los Angeles, California • San Diego, California + 4 more

Conditions: Neoplasms
Interventions: CC-95251, Rituximab, Cetuximab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 10 more

Conditions: Head and Neck Basaloid Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary Origin, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IV Oropharyngeal Squamous Cell Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer, Oropharyngeal Cancer, HNSCC, Stage IV Lip and Oral Cavity Squamous Cell Carcinoma
Interventions: Cetuximab, Ficlatuzumab; Biological · Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: Tucson, Arizona • New Haven, Connecticut • Tampa, Florida + 3 more

Conditions: Neoplasms
Interventions: feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more

About this Cetuximab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Cetuximab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Cetuximab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Cetuximab clinical trials

Filter and sort this therapy

Live official records

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

PhII ICb With/Without Erbitux in MBC Pts

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

About this Cetuximab clinical trials directory page